Utilisation and safety of bemiparin, a low-molecular-weight heparin, in medical patients: A prospective, uncontrolled cohort study

Clinical Drug Investigation

Volumn 25, Issue 7, 2005, Pages 463-472

  Miras Parra, Francisco ^a   Navascués Martínez, Emilia ^a   Gómez Outes, Antonio ^b   Martínez González, Javier ^b,d   Rocha, Eduardo ^c  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b Lab Farmaceuticos Rovi S A   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BEMIPARIN; CLOPIDOGREL; CORTICOSTEROID; DICLOFENAC; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDOMETACIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE; TRIFLUSAL;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN DISEASE; BRAIN INFARCTION; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG UTILIZATION; ECCHYMOSIS; FEMALE; FIBRINOLYTIC THERAPY; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HEMATOMA; HEPATITIS C; HOSPITALIZATION; HUMAN; INJECTION SITE REACTION; KIDNEY DISEASE; KIDNEY FAILURE; LUNG DISEASE; LUNG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RISK ASSESSMENT; SEPSIS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 22544463642     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525070-00005     Document Type: Article

References (28)

1. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991 Mar 23; 302 (6778): 709-11
2. McKelvie PA. Autopsy evidence of pulmonary thromboembolism. Med J Aust 1994 Feb 7; 160 (3): 127-8
3. Alikhan R, Peters F, Wilmott R, et al. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004 Dec; 57 (12): 1254-7
4. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000 Jan; 83 (1): 14-9
5. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004 Sep; 126 (3 Suppl.): 338S-400S
6. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001 Mar; 20 (1): 1-37
7. Kakkar VV, Howes J, Sharma V, et al. A comparative, doubleblind, randomized trial of a new-second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost 2000 Apr; 83 (4): 523-9
8. Planes A. Review on bemiparin sodium, a new second generation low-molecular-weight heparin, and its applications in venous thromboembolism. Expert Opin Pharmacother 2003 Sep; 4 (9): 1551-61
9. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs 2003; 63 (21): 2357-77
10. Westmuckett AD, Kakkar VV, Hamuro T, et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001 Dec; 86 (6): 1547-54
11. De Lorenzo F, Newberry D, Scully M, et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002 Apr; 143 (4): 689-95
12. Moreno González E, Fontcuberta J, de la Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology 1996; 43: 744-7
13. Hidalgo M, Figueroa JM. Prophylaxis of venous thromboembolism in abdominal wall surgery. Hernia 2000; 4: 242-7
14. Navarro-Quilis A, Castellet E, Rocha E, et al. Efficacy and safety of bemiparin compared with Enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized double-blind clinical trial. J Thromb Haemost 2003 Mar; 1 (3): 425-32
15. Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consen sus Group. BMJ 1992 Sep 5; 305 (6853): 567-74
16. Alikhan R, Cohen AT, Combe S, et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004 May 10; 164 (9): 963-8
17. Arcelus JI, Candocia S, Traverso CI, et al. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17 (Suppl.3): 313-8
18. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis score. J Thromb Haemost 2004 Dec; 2 (12): 2156-61
19. Alonso Ortiz del Rio C, Medrano Ortega FJ, Romero Alonso A, et al. Prevention of thromboembolic venous disease in medical patients (PRETEMED). Available from URL: http:// www.guideline.gov [Accessed 30 May 2005]
20. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med 1999 Sep 9; 341 (11): 793-800
21. Leizorovicz A, Cohen AT, Turpie AG, et al. for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004 Aug 17; 110 (7): 874-9
22. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26 (3): 197-207
23. Villar Fernandez I, Urbieta Sanz E, Arenere Mendoza M, et al. Assessing the use of low-molecular-weight heparins for venous thromboembolism prophylaxis in internal medicine patients [in Spanish]. Farm Hosp 2004 Nov-Dec; 28 (6): 402-9
24. Monreal M, Kakkar AK, Caprini JA, et al. RIETE Investigators. The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2004 Nov; 2 (11): 1892-8
25. Elis A, Ellis MH. Preventing venous thromboembolism in acute medical patients. QJM 2004 Dec; 97 (12): 797-801
26. Stinnett JM, Pendleton R, Skordos L, et al. Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol 2005 Mar; 78 (3): 167-72
27. Leizorovicz A, Mismetti P. Preventing venous thromboembo lism in medical patients. Circulation 2004 Dec 14; 110 (24 Suppl. 1): IV13-9
28. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989 Apr; 82 (4): 203-5